Quality of life among germ-cell testicular cancer survivors: The effect of time since cancer diagnosis.


Journal

PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081

Informations de publication

Date de publication:
2021
Historique:
received: 12 02 2021
accepted: 22 09 2021
entrez: 6 10 2021
pubmed: 7 10 2021
medline: 26 11 2021
Statut: epublish

Résumé

Testicular cancer is one of the most treatable cancers, with a 10-year survival of more than 95%. Many patients will be long-term survivors and this disease strikes men in an important phase of their lives, therefore the quality of life (QoL) among these patients is an area of particular interest. We aimed to study whether QoL in testicular cancer survivors depends on the time since cancer diagnosis. Data were collected from the EPSAM (Esposizioni postnatali e salute maschile) study, a case-control study on patients with testicular cancer, diagnosed between 1997 and 2008 in the province of Turin, Northern Italy, and interviewed between 2008 and 2010 (response rate among cases 57%). Patients were contacted through their oncologist at the San Giovanni Batista Hospital in Turin or through their general practitioner (GP) in the rest of the Province of Turin. QoL was assessed cross-sectionally using the short form 12 (SF-12) questionnaire, a generic short-form health survey that produces two summary scores, PCS (physical component score) and MCS (mental component score), to evaluate physical and mental health, respectively. Out of 234 study patients, 125 cases were seminomas and 109 cases were nonseminomas. The mean age at diagnosis was 34.5 years. After adjusting for age, time since diagnosis was not associated with PCS and MCS scores. Among nonseminomas, the median PCS slightly increased (adjusted OR (odds ratio) for 5+ vs < 2 years since cancer diagnosis: 1.78 (1.17-2.73), p = 0.008) and MCS slightly decreased (adjusted OR per 1-year increase since cancer diagnosis: 0.92, 95% CI: 0.82-1.05, p = 0.23) with time. Similar findings of no association between time since diagnosis and PCS and MCS were found when the analyses were restricted to the subgroup of cancer patients contacted through their oncologist, whose response proportion was 82%. In a study of testicular cancer patients interviewed cross-sectionally at 1 to more than 10 years since diagnosis, time since cancer diagnosis was not associated with QoL when we considered all germ-cell testicular cancer patients together. When stratified by histology type, we found certain evidence that nonseminoma cases report higher PCS over time since cancer diagnosis.

Identifiants

pubmed: 34614027
doi: 10.1371/journal.pone.0258257
pii: PONE-D-21-04801
pmc: PMC8494333
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e0258257

Déclaration de conflit d'intérêts

The authors have declared that no competing interests exist.

Références

Eur J Cancer. 2003 Jun;39(9):1216-21
pubmed: 12763208
J Clin Oncol. 2003 Apr 1;21(7):1249-54
pubmed: 12663711
Cancer Nurs. 2015 Jan-Feb;38(1):E29-54
pubmed: 24831042
J Clin Oncol. 2005 May 1;23(13):3061-8
pubmed: 15860864
Qual Life Res. 2011 Dec;20(10):1629-37
pubmed: 21499930
Int J Cancer. 2014 Aug 1;135(3):695-701
pubmed: 24375202
J Natl Cancer Inst. 2010 Aug 4;102(15):1114-30
pubmed: 20585105
J Clin Oncol. 2005 Apr 1;23(10):2389-95
pubmed: 15800331
Int J Cancer. 1999 Dec 10;83(6):860-3
pubmed: 10597212
Stat Med. 2010 Jan 30;29(2):309-17
pubmed: 19941281
J Clin Epidemiol. 1998 Nov;51(11):1171-8
pubmed: 9817135
Int J Urol. 1997 Sep;4(5):487-92
pubmed: 9354952
J Urol. 1996 Feb;155(2):574-8
pubmed: 8558663
J Natl Cancer Inst. 2000 Jul 19;92(14):1165-71
pubmed: 10904090
Int J Cancer. 2017 Nov 1;141(9):1803-1810
pubmed: 28699204
Urol Oncol. 2005 May-Jun;23(3):193-200
pubmed: 15907721
Eur J Cancer. 2004 Jul;40(11):1696-703
pubmed: 15251159
Med Care. 1996 Mar;34(3):220-33
pubmed: 8628042
Int J Cancer. 2007 Feb 1;120(3):623-31
pubmed: 17096341
Support Care Cancer. 2004 Jul;12(7):476-86
pubmed: 15179563
J Clin Oncol. 2003 Apr 15;21(8):1513-23
pubmed: 12697875
J Clin Oncol. 1993 Apr;11(4):598-606
pubmed: 8386751
J Clin Oncol. 2002 Jan 1;20(1):73-80
pubmed: 11773156
Med Care. 1994 Jan;32(1):40-66
pubmed: 8277801
J Cancer Surviv. 2016 Apr;10(2):223-33
pubmed: 26178326
J Clin Oncol. 2018 May 20;36(15):1505-1512
pubmed: 29617189
IARC Sci Publ. 1992;(120):45-173
pubmed: 1284606
Eur Rev Med Pharmacol Sci. 2018 Feb;22(3):645-661
pubmed: 29461592
J Clin Oncol. 1998 Oct;16(10):3386-91
pubmed: 9779717
J Epidemiol Biostat. 2001;6(3):305-16
pubmed: 11437095
Semin Surg Oncol. 1999 Dec;17(4):275-81
pubmed: 10588857
Psychooncology. 2018 Apr;27(4):1129-1137
pubmed: 29171109

Auteurs

Aleksandar Jovanovski (A)

Cancer Epidemiology Unit, Department of Medical Sciences, University of Turin and CPO-Piemonte, Torino, Italy.
Department of Clinical and Biological Sciences, University of Turin, Turin, Italy.

Daniela Zugna (D)

Cancer Epidemiology Unit, Department of Medical Sciences, University of Turin and CPO-Piemonte, Torino, Italy.

Daniela Di Cuonzo (D)

Cancer Epidemiology Unit, Department of Medical Sciences, University of Turin and CPO-Piemonte, Torino, Italy.

Patrizia Lista (P)

Medical Oncology Division 1, University Hospital "Citta' della Salute e della Scienza", Turin, Italy.

Libero Ciuffreda (L)

Medical Oncology Division 1, University Hospital "Citta' della Salute e della Scienza", Turin, Italy.

Franco Merletti (F)

Cancer Epidemiology Unit, Department of Medical Sciences, University of Turin and CPO-Piemonte, Torino, Italy.

Rosalba Rosato (R)

Cancer Epidemiology Unit, Department of Medical Sciences, University of Turin and CPO-Piemonte, Torino, Italy.
Department of Psychology, University of Turin, Turin, Italy.

Lorenzo Richiardi (L)

Cancer Epidemiology Unit, Department of Medical Sciences, University of Turin and CPO-Piemonte, Torino, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH